Company: BOLT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058632
Chunk: 0

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934</div>

Filed by the Registrant ☒

Filed by a party other than the Registrant ☐

Check the appropriate box:

Preliminary Proxy Statement

Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒ Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12

<div align='center'>Bolt Biotherapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

Not applicable</div>

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required

Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

900 Chesapeake Drive Redwood City, California 94063 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 27, 2025 AT 11:00 A.M. PACIFIC TIME Dear Stockholder: You are cordially invited to attend the 2025 Annual Meeting of Stockholders of Bolt Biotherapeutics, Inc., a Delaware corporation, or the Company or Bolt Bio. The 2025 Annual Meeting of Stockholders will be held on May 27, 2025, at 11:00 a.m., Pacific Time. The 2025 Annual Meeting of Stockholders will be convened and held entirely online. You will be able to attend and participate online in the 2025 Annual Meeting of Stockholders by visiting www.proxydocs.com/BOLT , where you will be able to listen to the meeting live, submit questions, and vote. The 2025 Annual Meeting of Stockholders is being convened to conduct the following business: 1. To elect our two nominees for Class I directors to serve until our 2028 Annual Meeting of Stockholders; 2. To ratify the selection by the audit committee of the Board of Directors of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2025; 3. Approval of an